Literature DB >> 22277475

[Progressive multifocal leukoencephalopathy (PML)].

Hidehiro Mizusawa1, Shuji Kishida, Masayuki Saijo, Motohiro Yukishita, Yukiko Shishido-Hara, Hirohumi Sawa, Kazuo Nagashima, Souichi Nukuzuma, Masahito Yamada.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of latently infected JCV when hosts' immune system is impaired by HIV infection, hematologic diseases, collagen diseases, immunemodulatory therapy and so on. PML was rare but HIV infection and Natalizumab have made it much more common while the prognosis is much better than other PML. PML patients present with various signs and symptoms including hemiparesis, dementia, aphasia, visual disturbance, cranial nerve paresis, cerebellar signs and bladder bowel disturbance. Brain MRI reveals characteristic demyelinating lesions in the CNS white matter and CSF mild increase of protein with or without mild mononuclear pleocytosis. Detection of JCV genome from CSF is crucial for the clinical diagnosis of PML. PML was once thought to be fatal but some HIV infected PML patients showed halting progression or even recovery after introduction of HAART. In addition, anti-malarial drug mefloquine was found to be effective. Recovery of immunity may provoke some inflammatory responses known as immune reconstruction inflammatory syndrome (IRIS) which requires high dose corticosteroid. In Japan, we are providing free test of CSF-JCV genome and organized a unique system for surveillance and clinical research of PML. Using this system we hope to improve diagnosis and therapy of PML in Japan.

Entities:  

Mesh:

Year:  2011        PMID: 22277475     DOI: 10.5692/clinicalneurol.51.1051

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  1 in total

1.  The Effect of Intravenous Methylprednisolone on Recurrent Exacerbation in Hematologic Malignancy-associated Progressive Multifocal Leukoencephalopathy.

Authors:  Ryutaro Nakamura; Akihiro Kitamura; Takahito Tsukamoto; Ryota Tamura; Nobuhiro Ogawa; Isamu Yamakawa; Hyoh Kim; Michihiro Kawai; Mitsuru Sanada; Makoto Urushitani
Journal:  Intern Med       Date:  2020-11-23       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.